Literature DB >> 2903792

Oncological applications of somatostatin analogues.

A V Schally1.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 2903792

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  90 in total

1.  Molecular Events as Targets of Anticancer Drug Therapy.

Authors:  Adorján Aszalós; Sándor Eckhardt
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 2.  The therapeutic value of somatostatin and its analogues.

Authors:  S Farooqi; J S Bevan; M C Sheppard; J A Wass
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

Review 3.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 4.  Nuclear imaging of molecular processes in cancer.

Authors:  Rafael Torres Martin de Rosales; Erik Arstad; Philip J Blower
Journal:  Target Oncol       Date:  2009-09-25       Impact factor: 4.493

5.  Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin.

Authors:  W A Banks; A V Schally; C M Barrera; M B Fasold; D A Durham; V J Csernus; K Groot; A J Kastin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.

Authors:  P Cordelier; J P Estève; C Bousquet; N Delesque; A M O'Carroll; A V Schally; N Vaysse; C Susini; L Buscail
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

7.  Cloning and characterization of a fourth human somatostatin receptor.

Authors:  L Rohrer; F Raulf; C Bruns; R Buettner; F Hofstaedter; R Schüle
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

8.  Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas.

Authors:  Elaine Lu Wang; Zhi Rong Qian; Shozo Yamada; Md Mustafizur Rahman; Naoko Inosita; Teruyoshi Kageji; Hideko Endo; Eiji Kudo; Toshiaki Sano
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

Review 9.  Hormonal therapy of pancreatic carcinoma. Rationale and perspectives.

Authors:  D Perilli; C Mansi; V Savarino; G Celle
Journal:  Int J Pancreatol       Date:  1993-06

10.  Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.

Authors:  K Szepeshazi; S Milovanovic; K Lapis; K Groot; A V Schally
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.